We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.43 | 0.33% | 131.15 | 131.91 | 130.13 | 130.13 | 7,757,432 | 00:26:37 |
From Oct 2023 to Apr 2024
By Colin Kellaher
Shares of Harpoon Therapeutics doubled in premarket trading Monday after Bloomberg reported that the clinical-stage immunotherapy company is near a deal to be acquired by drugmaker Merck & Co. at a rich premium.
Merck is discussing paying about $700 million, or around $23 a share, for Harpoon, more than double Friday's closing price of $10.55 for the South San Francisco, Calif., company, Bloomberg reports, citing people familiar with the matter.
Merck, based in Rahway, N.J., could announce a deal within days, according to the report.
Harpoon shares were recently up 100% to $21.08 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 08, 2024 06:32 ET (11:32 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
